OTC · Healthcare
INTEGRATED BIOPHARMA INC (INBP)
As-reported financials and recent SEC filings for INTEGRATED BIOPHARMA INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$54.4M
Net income
$808,000
Net margin
1.5%
Diluted EPS
$0.03
ROE
4.0%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $54.4M | $50.3M | $50.7M | $56.2M | $63.6M |
| Gross profit | $5.6M | $3.9M | $4.1M | $6.6M | $9.5M |
| Operating income | $2.0M | $251,000 | $120,000 | $2.7M | $5.8M |
| Net income | $808,000 | $112,000 | $-34,000 | $3.8M | $8.0M |
| Diluted EPS | $0.03 | $0.00 | $0.00 | $0.12 | $0.25 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-07-02
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →4/A2026-06-25
View on EDGAR →42026-06-25
View on EDGAR →8-K2026-05-08
View on EDGAR →10-Q2026-05-08
View on EDGAR →Largest Healthcare peers
Go deeper on INBP
Search INTEGRATED BIOPHARMA INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.